絞り込み

16599

広告

1144件中 81件~100件表示    検索結果をPubMedで見る PubMedで見る

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.

Discovery of Non-peptide, Reversible HER1/HER2 Dual-Targeting Small Molecule Inhibitors as NIR Fluorescent Probe for Efficient Tumor Detection, Diagnostic Imaging and Drug Screening.

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.

Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway.

Palbociclib overcomes afatinib resistance in non-small cell lung cancer.

Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.

Miliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report.

Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

Periocular Manifestations of Afatinib Therapy.

Cryoprotectant toxicity in Caenorhabditis elegans.

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.

A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.

Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.

Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis.

Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling.

Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.

The effects of switching EGFR-TKI treatments for nonsmall cell lung cancer because of adverse events.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります